SAN DIEGO, March 22 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the hiring of Carol G. Gallagher, Pharm. D., as Vice President, Commercial Affairs. Dr. Gallagher will be responsible for commercial affairs, including business development, market planning and strategic planning.
“We are very pleased that Carol is joining Anadys,” said Kleanthis G. Xanthopoulos, Ph.D., Anadys’ President and Chief Executive Officer. “Her leadership and experience in managing many therapeutic agents with multiple partners on a worldwide basis will be critical to Anadys as we build the foundation of our commercialization strategy.”
“Throughout her career, Carol has had success in multiple positions of increasing leadership responsibilities,” said Steve Worland, Ph.D., Anadys’ Executive Vice President, Pharmaceuticals. “Anadys is fortunate to have someone with her talent, vision, energy and commitment. She will be an outstanding addition to our company.”
Dr. Gallagher joins Anadys on April 3, 2006 and will report to Dr. Worland.
Prior to joining Anadys, Dr. Gallagher was the Vice President, Sales, Marketing and Product Planning at CancerVax Corporation, where she was employed since December 2003. From January 2002 to November 2003 Dr. Gallagher was Senior Director of Oncology Marketing at Biogen Idec, Inc. During that time, her role included leadership of the Rituxan(R) collaboration with Genentech, Inc. Previously, Dr. Gallagher was Director, Global Marketing Planning for Oncology and Ophthalmology at Pfizer, Inc. She also held other marketing positions, including product and new product management roles at Agouron Pharmaceuticals, prior to its acquisition by Pfizer. From 1989 to 1997, she held various sales and marketing positions at both Eli Lilly and Co. and Amgen, Inc. Dr. Gallagher holds a Doctor of Pharmacy degree from the University of Kentucky.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of hepatitis, other serious infections, and cancer. The Company has core expertise in Toll-Like Receptor-based small-molecule therapeutics and structure-based drug design coupled with medicinal chemistry. Anadys’ clinical development programs include ANA975 for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. In addition, Anadys’ therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, references to the plan for Dr. Gallagher to develop Anadys’ commercialization strategy and assist with forward integration, as well as the expected impact that Dr. Gallagher will have on building the foundation of Anadys’ commercialization strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys’ actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular, the results of initial clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will have favorable results in future clinical trials, receive regulatory approval, or be commercialized. In addition, Anadys’ results may be affected by risks related to its collaborative relationships with Novartis and LG Life Sciences, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. These and other factors that may cause actual results to differ are more fully discussed in the “Risk Factors” section of Anadys’ Form 10-K for the year ended December 31, 2005. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com
Web site: http://www.anadyspharma.com//
